On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US.
By
Clark Herman
| Published: August 1, 2013
On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US. These priorities signal public and private policymakers alike to improve the way patients take their medication.
In 2009, NEHI published research which found that people with poor medication adherence, either by not taking their medication accordingly or not at all, cost the US health care system $290 billion annually. In addition to this research, the Congressional Budget Office published its own study describing the beneficial impact of adherence to therapy; with a projected 5% increase from exposure of Medicare to cover drugs would lead to a 1% decrease in the programs medical and hospital spending.
NEHI’s new report, which resulted from a series of roundtables on adherence in 2012, focuses on the following six points in developing a comprehensive, system-wide solution:
For more information, visit NEHI’s website: http://www.nehi.net
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.